BRAIN METASTASIS AND HER-2 STATUS IN METASTATIC BREAST CANCER (MBC) IN OMAN

被引：0
|
作者：
Monem, E. Abdul [1 ]
Mehdi, I. [1 ]
Al Bahrani, B. [1 ]
机构：
[1] Royal Hosp, Muscat, Oman
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
121P
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [31] The significance of histological determination of HER-2 status in breast cancer
    Walker, RA
    BREAST, 2000, 9 (03): : 130 - 133
  • [32] Serum TIMP-1 and HER-2/neu levels in metastatic breast cancer (MBC) treated with either letrozole or tamoxifen
    Hamer, P. J.
    Lipton, A.
    Leitzel, K.
    Demers, L.
    Ali, S. M.
    Evans, D. B.
    Chaudri-Ross, H. A.
    Brown-Shimer, S.
    Pierce, K.
    Carney, W. P.
    Gaur, V.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A156 - A156
  • [33] DOCETAXEL (D), GEMCITABINE (G) AND BEVACIZUMAB (BEV) AS SALVAGE CHEMOTHERAPY (CT) FOR HER-2 NEGATIVE METASTATIC BREAST CANCER (MBC)
    Kontopodis, E.
    Christophylakis, C.
    Kentepozidis, N.
    Boukovinas, I.
    Giassas, S.
    Saloustros, E.
    Kalykaki, A.
    Bozionelou, V.
    Georgoulias, V.
    Mavroudis, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 139 - 139
  • [34] Cost-effectiveness of HER-2 testing strategies to select women with metastatic breast cancer (MBC) for treatment with trastuzumab.
    Oster, G
    Delea, TE
    Berger, A
    Klein, P
    Lieberman, G
    Paton, VE
    Chawla, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 68S - 68S
  • [35] Correlation between Her-2 status in primary tumour and response to anastrozole in patients with metastatic breast cancer
    Drev, P.
    Golouh, R.
    Snoj, N.
    Cufer, T.
    EJC SUPPLEMENTS, 2004, 2 (03): : 178 - 178
  • [36] Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature
    Arslan, Cagatay
    Sari, Ebru
    Aksoy, Sercan
    Altundag, Kadri
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) : 21 - 30
  • [37] HER-2 expression on circulating tumor cells in metastatic breast cancer
    Hayashi, H.
    Yagata, H.
    Hamaoka, T.
    Sarumaru, S.
    Tsugawa, K.
    Yoshida, A.
    Tsunoda-Shimizu, H.
    Suzuki, K.
    Shimada, M.
    Shimoda, Y.
    Nakamura, S.
    CANCER RESEARCH, 2009, 69 (02) : 306S - 307S
  • [38] Substantial reduction in the percentage of metastatic breast cancer (MBC) which is HER-2 positive (HER-2+) over two decades: Sequential cohort analysis from the 1000 patient HER-2 study
    Berenguer-Pina, J. J.
    Quinn, C. M.
    Gullo, G.
    Skrobo, D.
    Buckley, C.
    Walshe, J. M.
    Fennelly, D.
    Higgins, M.
    Ballot, J.
    Mccartan, D.
    Walsh, N.
    Crown, J. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S499 - S499
  • [39] Male HER-2 positive metastatic breast cancer: A case report
    Lin, Na
    Xu, Qianhui
    Wang, Bing
    Dang, Yuan
    Lin, Chen
    ASIAN JOURNAL OF SURGERY, 2020, 43 (12) : 1175 - 1176
  • [40] Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer
    Cardoso F.
    Breast Cancer Research, 3 (1)
12345